- Home
- RMBI vs ATOS Comparison
RMBI vs ATOS Comparison
Compare RMBI & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMBI
- ATOS
- Stock Information
- Founded
- RMBI 1887
- ATOS 2009
- Country
- RMBI United States
- ATOS United States
- Employees
- RMBI N/A
- ATOS N/A
- Industry
- RMBI Major Banks
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- RMBI Finance
- ATOS Health Care
- Exchange
- RMBI Nasdaq
- ATOS Nasdaq
- Market Cap
- RMBI 134.9M
- ATOS 113.7M
- IPO Year
- RMBI 2019
- ATOS 2012
- Fundamental
- Price
- RMBI $13.19
- ATOS $0.83
- Analyst Decision
- RMBI
- ATOS Strong Buy
- Analyst Count
- RMBI 0
- ATOS 3
- Target Price
- RMBI N/A
- ATOS $7.00
- AVG Volume (30 Days)
- RMBI 15.7K
- ATOS 886.8K
- Earning Date
- RMBI 01-31-2025
- ATOS 11-12-2024
- Dividend Yield
- RMBI 4.25%
- ATOS N/A
- EPS Growth
- RMBI N/A
- ATOS N/A
- EPS
- RMBI 0.87
- ATOS N/A
- Revenue
- RMBI $42,258,740.00
- ATOS N/A
- Revenue This Year
- RMBI N/A
- ATOS N/A
- Revenue Next Year
- RMBI N/A
- ATOS N/A
- P/E Ratio
- RMBI $15.18
- ATOS N/A
- Revenue Growth
- RMBI N/A
- ATOS N/A
- 52 Week Low
- RMBI $10.11
- ATOS $0.77
- 52 Week High
- RMBI $15.15
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- RMBI 45.51
- ATOS 27.85
- Support Level
- RMBI $12.26
- ATOS $0.91
- Resistance Level
- RMBI $13.01
- ATOS $0.94
- Average True Range (ATR)
- RMBI 0.53
- ATOS 0.06
- MACD
- RMBI -0.05
- ATOS -0.00
- Stochastic Oscillator
- RMBI 53.73
- ATOS 1.62
About RMBI Richmond Mutual Bancorporation Inc.
Richmond Mutual Bancorp Inc is a United States-based banking company. Its principal business consists of attracting deposits from the general public & brokered deposits and investing those funds predominantly in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one-to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.